Verition Fund Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.5M | Buy |
410,164
+314,789
| +330% | +$17.1M | 0.09% | 231 |
|
|
2026
Q1 | $5.98M | Buy |
95,375
+47,438
| +99% | +$3.79M | 0.04% | 506 |
|
|
2025
Q4 | $4.57M | Sell |
47,937
-94,434
| -66% | -$9.26M | 0.02% | 946 |
|
|
2025
Q3 | $13.9M | Buy |
142,371
+4,503
| +3% | +$466K | 0.06% | 347 |
|
|
2025
Q2 | $14.8M | Sell |
137,868
-197,653
| -59% | -$20M | 0.07% | 340 |
|
|
2025
Q1 | $33.8M | Buy |
335,521
+314,559
| +1,501% | +$31.7M | 0.16% | 94 |
|
|
2024
Q4 | $1.87M | Buy |
20,962
+5,187
| +33% | +$457K | 0.01% | 1595 |
|
|
2024
Q3 | $1.32M | Sell |
15,775
-60,708
| -79% | -$4.79M | 0.01% | 1689 |
|
|
2024
Q2 | $5.89M | Buy |
76,483
+29,674
| +63% | +$2.17M | 0.03% | 625 |
|
|
2024
Q1 | $3.21M | Buy |
46,809
+19,294
| +70% | +$1.24M | 0.02% | 955 |
|
|
2023
Q4 | $1.59M | Sell |
27,515
-1,042
| -4% | -$55.6K | 0.01% | 951 |
|
|
2023
Q3 | $1.51M | Sell |
28,557
-15,832
| -36% | -$830K | 0.02% | 900 |
|
|
2023
Q2 | $2.4M | Buy |
44,389
+36,761
| +482% | +$1.92M | 0.03% | 598 |
|
|
2023
Q1 | $382K | Sell |
7,628
-9,603
| -56% | -$453K | 0.01% | 1386 |
|
|
2022
Q4 | $797K | Buy |
+17,231
| New | +$746K | 0.01% | 1026 |
|
|
2022
Q3 | – | Sell |
-20,688
| Closed | -$830K | – | 3050 |
|
|
2022
Q2 | $771K | Buy |
20,688
+10,320
| +100% | +$420K | 0.02% | 1171 |
|
|
2022
Q1 | $459K | Sell |
10,368
-28,411
| -73% | -$1.23M | 0.01% | 1948 |
|
|
2021
Q4 | $1.65M | Buy |
+38,779
| New | +$1.63M | 0.01% | 1002 |
|
|
2021
Q3 | – | Sell |
-28,768
| Closed | -$1.23M | – | 1930 |
|
|
2021
Q2 | $1.23M | Buy |
+28,768
| New | +$1.21M | 0.01% | 714 |
|
|
2021
Q1 | – | Sell |
-20,071
| Closed | -$722K | – | 1556 |
|
|
2020
Q4 | $722K | Buy |
20,071
+6,303
| +46% | +$227K | 0.01% | 568 |
|
|
2020
Q3 | $526K | Buy |
+13,768
| New | +$531K | 0.01% | 563 |
|
|
2020
Q1 | – | Sell |
-8,467
| Closed | -$383K | – | 649 |
|
|
2019
Q4 | $383K | Sell |
8,467
-7,927
| -48% | -$332K | 0.01% | 767 |
|
|
2019
Q3 | $667K | Buy |
+16,394
| New | +$695K | 0.02% | 528 |
|
|
2019
Q2 | – | Sell |
-14,872
| Closed | -$571K | – | 1080 |
|
|
2019
Q1 | $571K | Buy |
+14,872
| New | +$568K | 0.02% | 605 |
|
|
2018
Q2 | – | Sell |
-45,571
| Closed | -$1.25M | – | 1087 |
|
|
2018
Q1 | $1.25M | Sell |
45,571
-8,748
| -16% | -$238K | 0.09% | 289 |
|
|
2017
Q4 | $1.35M | Buy |
+54,319
| New | +$1.5M | 0.12% | 170 |
|
|
2017
Q2 | – | Sell |
-8,669
| Closed | -$216K | – | 950 |
|
|
2017
Q1 | $216K | Sell |
8,669
-21,107
| -71% | -$513K | 0.02% | 1004 |
|
|
2016
Q4 | $644K | Buy |
29,776
+2,922
| +11% | +$63.8K | 0.06% | 426 |
|
|
2016
Q3 | $639K | Sell |
26,854
-6,770
| -20% | -$162K | 0.07% | 380 |
|
|
2016
Q2 | $786K | Buy |
33,624
+16,276
| +94% | +$352K | 0.1% | 235 |
|
|
2016
Q1 | $326K | Sell |
17,348
-829
| -5% | -$14.6K | 0.05% | 447 |
|
|
2015
Q4 | $335K | Buy |
+18,177
| New | +$326K | 0.06% | 274 |
|
|
2014
Q4 | – | Sell |
-23,175
| Closed | -$274K | – | 385 |
|
|
2014
Q3 | $274K | Sell |
23,175
-25,441
| -52% | -$320K | 0.04% | 430 |
|
|
2014
Q2 | $621K | Buy |
+48,616
| New | +$632K | 0.07% | 197 |
|
|
2014
Q1 | – | Sell |
-12,270
| Closed | -$147K | – | 507 |
|
|
2013
Q4 | $147K | Sell |
12,270
-51,249
| -81% | -$605K | 0.03% | 421 |
|
|
2013
Q3 | $746K | Buy |
+63,519
| New | +$687K | 0.11% | 149 |
|
Other funds holding BSX
Verition Fund Management's BSX Position: Q2 2026 in Review
Verition Fund Management increased its Boston Scientific (BSX) stake by 330% in Q2 2026, buying an estimated $17.1M and bringing the position to 410,164 shares worth $17.5M. The position accounts for 0.09% of the portfolio, ranked #231.
Verition Fund Management first reported a position in BSX in Q3 2013 and has held it in 36 quarters since. The position peaked at $33.8M in Q1 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Verition Fund Management held 410,164 shares of Boston Scientific worth $17.5M as of Q2 2026.
- Verition Fund Management bought 314,789 Boston Scientific shares in Q2 2026, an estimated $17.1M.
- Boston Scientific made up 0.09% of Verition Fund Management's portfolio in Q2 2026, its #231 holding.
- Verition Fund Management first reported a position in Boston Scientific in Q3 2013 and has held it in 36 quarters since.
- Verition Fund Management's Boston Scientific position peaked at $33.8M in Q1 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.